search
Back to results

Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease

Primary Purpose

Pulmonary Insufficiency

Status
Terminated
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
iNO administered
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Insufficiency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Known pulmonary insufficiency status
  • Previous Tetralogy of Fallot repair or balloon valvuloplasty/surgical valvotomy for pulmonary stenosis
  • Clinically indicated cardiac magnetic resonance imaging study

Exclusion Criteria:

  • Enrollment in another clinical trial
  • Age less then 18 years
  • Inability to provide informed consent
  • Institutionalized individual
  • Pregnant or lactating
  • Serious claustrophobia
  • Pacemaker/ICD
  • Aneurysm clips
  • Internal hardware
  • Severe obesity (>350lbs)
  • Residual ventricular septal defect
  • History of methemoglobinemia
  • History of blood dyscrasias
  • Acute pulmonary infection
  • Pulmonary edema
  • Hypersensitivity to nitric oxide or any of its components
  • Left ventricle dysfunction (EF<40%)
  • Concurrent use of nitroglycerin or prilocaine

Sites / Locations

  • The Cleveland Clinic

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

iNO administered

Arm Description

iNO administered at 40 ppm via a non-rebreather mask

Outcomes

Primary Outcome Measures

pulmonary regurgitant volume and fraction
Aortic regurgitant fraction measured by CMR velocity flow mapping

Secondary Outcome Measures

Full Information

First Posted
October 11, 2007
Last Updated
January 26, 2017
Sponsor
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT00543933
Brief Title
Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease
Official Title
Acute Effect of Inhaled Nitric Oxide on Pulmonary Insufficiency in Congenital Heart Disease
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Terminated
Why Stopped
Investigator left institution
Study Start Date
October 2007 (Actual)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Cleveland Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Inhaled nitric oxide in patients with pulmonic valve insufficiency.
Detailed Description
Pulmonic valve insufficiency (PI) is a well-defined problem after primary surgical repair of Tetralogy of Fallot (TOF). Though well-tolerated for years, long-term PI can lead to structural changes in the right ventricle, the sequelae of which include right heart failure, arrhythmia, and sudden cardiac death. The only current treatment for severe symptomatic PI is pulmonic valve replacement. We hypothesize that inhaled nitric oxide (iNO), a selective pulmonary vasodilator, can acutely decrease PI as assessed by cardiac magnetic resonance imaging (CMR). Methods: 22 consecutive patients with PI in the setting of corrected TOF or post pulmonic valve balloon valvuloplasty will undergo a clinically indicated CMR. Nitric oxide gas will be delivered via facemask through a specialized delivery device at 40ppm. After 5 minutes, flow velocity mapping and gradient echo sequences will be repeated to assess pulmonary regurgitant fraction, right ventricular volumes, and ejection fraction. Nitric oxide will be discontinued after acquisition of the last picture. Wilcoxon rank-sum for paired data will be used to assess effect of intervention. Significance: If decreasing pulmonary vascular resistance decreases PI, medical therapy with long-acting pulmonary vasodilators may be an attractive therapeutic option with the goal of delaying or even obviating pulmonic valve replacement.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Insufficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
iNO administered
Arm Type
Experimental
Arm Description
iNO administered at 40 ppm via a non-rebreather mask
Intervention Type
Drug
Intervention Name(s)
iNO administered
Other Intervention Name(s)
Nitric Oxide
Intervention Description
iNO at 40 ppm through a non-rebreather mask for 5 minutes
Primary Outcome Measure Information:
Title
pulmonary regurgitant volume and fraction
Description
Aortic regurgitant fraction measured by CMR velocity flow mapping
Time Frame
Single time point

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Known pulmonary insufficiency status Previous Tetralogy of Fallot repair or balloon valvuloplasty/surgical valvotomy for pulmonary stenosis Clinically indicated cardiac magnetic resonance imaging study Exclusion Criteria: Enrollment in another clinical trial Age less then 18 years Inability to provide informed consent Institutionalized individual Pregnant or lactating Serious claustrophobia Pacemaker/ICD Aneurysm clips Internal hardware Severe obesity (>350lbs) Residual ventricular septal defect History of methemoglobinemia History of blood dyscrasias Acute pulmonary infection Pulmonary edema Hypersensitivity to nitric oxide or any of its components Left ventricle dysfunction (EF<40%) Concurrent use of nitroglycerin or prilocaine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Krasuski, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24006858
Citation
Hart SA, Devendra GP, Kim YY, Flamm SD, Kalahasti V, Arruda J, Walker E, Boonyasirinant T, Bolen M, Setser R, Krasuski RA. PINOT NOIR: pulmonic insufficiency improvement with nitric oxide inhalational response. J Cardiovasc Magn Reson. 2013 Sep 4;15(1):75. doi: 10.1186/1532-429X-15-75.
Results Reference
derived

Learn more about this trial

Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease

We'll reach out to this number within 24 hrs